Emyria (ASX:EMD) has added to its pipeline with the inclusion of a high potency and highly bioavailable ultra-pure cannabidiol dose form to its proprietary cannabinoid medicine pipeline, EMD-RX9.
The company said the development of EMD-RX9 follows a series of successful studies conducted over the last two quarters. It said EMD-RX9 builds on its current lower dose strength capsules, EMD-RX5 and EMD-RX7.
EMD-RX9 targets new and existing prescription indications with the FDA where high cannabidiol (CBD) dose exposures are clinically indicated.
Emyria said EMD-RX9 offers competitive advantages in its US-focused registration strategy by addressing the needs of patients who require a high CBD dose but prefer the convenience and tolerability advantages of a solid oral capsule dose over existing liquid oil alternatives.
CEO Dr Michael Winlo said, "The launch of EMD-RX9 builds on the recent commercialisation success of our low-dose CBD capsule, EMD-RX5 targeting the over-the-counter market. The higher dose strength and potency of EMD-RX9 will support Emyria’s US-focused registration programs by helping address the needs of patients requiring high CBD doses.
"We are confident EMD-RX9 will demonstrate superior bioavailability compared to Epidyolex oil based on earlier head-to-head preclinical PK studies performed with EMD-RX7 and, together with our Real-World Data insights, can help Emyria’s growing Ultra-Pure cannabinoid product pipeline address the unmet needs of large patient populations."